Vivos Inc
radiogel.comWhat Do They Do?
Sells IsoPet injectable radiation treatments for animal tumors through veterinary clinics, develops a related human cancer treatment for hospitals and oncology centers, and sells polymer materials for drug delivery.
10-K for FY2025, filed Mar 31, 2026Vivos Inc. (the “Company,” “we,” “us,” “our”) is a radiation oncology medical device company engaged in the development of its yttrium-90…View ↗
The plan is to incorporate the data assembled from our work with Isopet® in animal therapy to support the Company’s efforts in the…View ↗
The Company anticipates that potential customers for its Precision Radionuclide Therapy™ (PRnT™) products—RadioGel® for human applications…View ↗
For human applications (RadioGel®), potential customers would include hospitals, oncology centers, interventional radiologists, and medical…View ↗
The veterinary and medical communities are expected to recognize Precision Radionuclide Therapy™ as an effective treatment for many solid…View ↗
How Do They Make Money?
Revenue comes from IsoPet treatment sales and procedures, with revenue counted when an animal's treatment is completed; clinics also pay for certification, counted when certification is completed.
10-K for FY2025, filed Mar 31, 2026
-
10-K for FY2025, filed Mar 31, 2026
FY2025 revenue by product or service ↗
$68.4K
-
10-K for FY2025, filed Mar 31, 2026
$68.4K ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Services Treatments
Sold outright
10-K for FY2025, filed Mar 31, 2026 |
130% |
Services Treatments, FY2025
$88.9K Sources
|
Sold outright |
|
IsoPet
Sold outright
10-K for FY2025, filed Mar 31, 2026 |
209% |
IsoPet, FY2025
$143K Sources
|
Sold outright |
|
Certification
Licensed
10-K for FY2025, filed Mar 31, 2026 |
55% |
Certification, FY2025
$37.5K Sources
|
Licensed |
|
Freight
|
1.5% |
Freight, FY2025
$1.1K Sources
|
|
|
Polymer
|
1.5% |
Polymer, FY2025
$1.1K Sources
|
|
|
Discount Services
|
−105% |
Discount Services, FY2025
−$71.8K Sources
|
|
|
Discount Iso Pet
|
−177% |
Discount Iso Pet, FY2025
−$121.3K Sources
|
|
|
Discount Certifications
|
−15% |
Discount Certifications, FY2025
−$10K Sources
|
Who Are Their Customers?
Veterinary clinics, university veterinary hospitals and animal oncology practices buy IsoPet directly; human therapy is aimed at hospitals, oncology centers and medical professionals, with institutional adoption or partnerships planned.
10-K for FY2025, filed Mar 31, 2026The Company anticipates that potential customers for its Precision Radionuclide Therapy™ (PRnT™) products—RadioGel® for human applications…View ↗
For human applications (RadioGel®), potential customers would include hospitals, oncology centers, interventional radiologists, and medical…View ↗
The veterinary and medical communities are expected to recognize Precision Radionuclide Therapy™ as an effective treatment for many solid…View ↗
Do Revenues Turn Into Profits?
No. It lost $3.1M in FY2025.
10-K for FY2025, filed Mar 31, 2026
−$3.2MView ↗
10-K for FY2025, filed Mar 31, 2026
−$3.1MView ↗
10-K for FY2025, filed Mar 31, 2026
−$2.2MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 12, 2026
−$830.2KView ↗
- ▲ +29% (Loss)
- vs −$645.5K in Q2 FY2025
10-Q for Q2 FY2026, filed Aug 12, 2026
Open tableView ↗
Growing. Revenue grew 4.6x in 4 years, from $14.9K in FY2021 to $68.4K in FY2025, about 46% a year.
Polymer products
The older report centered on RadioGel for cancer treatment; the latest also describes selling polymer materials and a hydrogel platform for delivering medicines.
10-K for FY2022, filed Mar 1, 2023 10-K for FY2025, filed Mar 31, 2026Vivos Inc. is a radiation oncology medical device company engaged in the development of its yttrium-90 (“Y-90”) based brachytherapy device…View ↗
Vivos Inc. (the “Company,” “we,” “us,” “our”) is a radiation oncology medical device company engaged in the development of its yttrium-90…View ↗
Clinic certification
The older report described planned licensing to private clinics; the latest describes direct IsoPet sales and charging veterinary clinics for certification.
10-K for FY2022, filed Mar 1, 2023 10-K for FY2025, filed Mar 31, 2026The Company anticipates that future profits, if any, will be derived from direct sales of RadioGel™ (under the name IsoPet®) and related…View ↗
The Company anticipates that any near-term profits, if any, will be derived from direct sales of RadioGel® (under the name IsoPet®) and…View ↗
Who Do They Compete With?
Competes with General Electric Healthcare, C.R. Bard, GT MedTech, Sirtex, and Biocompatibles UK
10-K for FY2025, filed Mar 31, 2026There are a wide variety of cancer treatments approved and marketed in the U.S. and globally. General categories of treatment include…View ↗
Loading...
